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predictor factor of breast tumor progression
Catarina Rodrigues dos Santos1,2,5*, Isabel Fonseca3,5, Sérgio Dias4,5 and JC Mendes de Almeida2,5Abstract
Background: Among women, breast cancer (BC) is the leading cancer and the most common cause of
cancer-related death between 30 and 69 years. Although lifestyle and diet are considered to have a role in global BC
incidence pattern, the specific influence of dyslipidemia in BC onset and progression is not yet completely understood.
Methods: Fasting lipid profile (total cholesterol, LDL-C, HDL-C, and triglycerides) was prospectively assessed in 244
women with BC who were enrolled according to pre-set inclusion criteria: diagnosis of non-hereditary invasive
ductal carcinoma; selection for surgery as first treatment, and no history of treatment with lipid-lowering or anti-
diabetic drugs in the previous year. Pathological and clinical follow-up data were recorded for further inclusion in
the statistical analysis.
Results: Univariate associations show that BC patients with higher levels of LDL-C at diagnosis have tumors that
are larger, with higher differentiation grade, higher proliferative rate (assessed by Ki67 immunostaining), are more
frequently Her2-neu positive and are diagnosed in more advanced stages. Cox regression model for disease-free
survival (DFS), adjusted to tumor T and N stages of TNM classification, and immunohistochemical subtypes, revealed
that high LDL-C at diagnosis is associated with poor DFS. At 25 months of follow up, DFS is 12% higher in BC pa-
tients within the third LDL-C tertile compared to those in the first tertile.
Conclusions: This is a prospective study where LDL-C levels, at diagnosis, emerge as a prognostic factor; and this
parameter can be useful in the identification and follow-up of high-risk groups. Our results further support a pos-
sible role for systemic cholesterol in BC progression and show that cholesterol metabolism may be an important
therapeutic target in BC patients.
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Cancer and cardiovascular diseases are the leading causes
of death in Europe [1] and USA [2] and their incidence is
increasing also in Asia [3,4].
In what concerns cancer, breast cancer (BC) is the
most frequent diagnosed each year in Europe and USA
(age–adjusted incidence rate, 76–89,7 per 100,000) [5] and
the most common cause of cancer-related death between
30 and 69 years [4]. In Asia, incidence rate of BC is lower
(age–adjusted incidence rate, 22–30 per 100,000) [5] but
is dramatically raising [4,6].* Correspondence: catarinarsantos@hotmail.com
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article, unless otherwise stated.Lifestyle and diet are frequently indicated as reasons
for the global distribution of BC incidence. Nevertheless,
while dyslipidemia [high LDL-C (low density lipoprotein
cholesterol) and low HDL-C (high density lipoprotein
cholesterol) levels] was already shown to play a major
role in the etiopathogenesis of cardiovascular diseases
[7], mainly attributed to diet, the specific influence of dys-
lipidemia in BC initiation and progression is not com-
pletely understood.
Cholesterol is a structural component of the cell mem-
brane, specially localized in lipid rafts - membrane micro-
domains that assemble the signal transduction machinery
and associate to proteins implicated in key cellular signal-
ing pathways. Many of these pathways closely associate
with malignant transformation due to their influence inioMed Central Ltd. This is an Open Access article distributed under the terms of
tp://creativecommons.org/licenses/by/2.0), which permits unrestricted use,
, provided the original work is properly credited. The Creative Commons Public
mons.org/publicdomain/zero/1.0/) applies to the data made available in this
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genesis [8,9].
Furthermore, cholesterol is also a steroid hormone
precursor and the vast majority of BC is known to be
hormone responsive [10]. The peak incidence of BC oc-
curs in the perimenopausal age [11], when women dys-
lipidemia prevalence also rises [12].
Several authors have shown that lipoprotein fractions
can induce cancer cells proliferation and migration
in vitro [13-19] and oxysterol 27-hydroxycholesterol, a
primary metabolite of cholesterol was shown to promote
ER–positive BC growth in in vivo models [20]. Moreover,
studies in genetic or diet induced hypercholesterolemic
mouse models also demonstrated a clear association be-
tween high lipid levels and BC development [21] and pro-
gression [22,23].
However, clinical data have provided contradictory re-
sults. Prospective studies showed positive association be-
tween total cholesterol (TC) levels and both BC incidence
[24-26] and increased overall mortality in BC patients
[27]; but also no association at all [28-33] or even inverse
associations between TC levels and incidence of premeno-
pausal BC [34-36]; as well as a protective effect of very
high levels of TC [37].
LDL-C and HDL-C are lipoproteins responsible for the
cholesterol transportation, LDL-C from the liver to periph-
eral tissues and HDL-C for the reverse transportation [38].
Studies specifically addressing the relation of lipoproteins
fractions are similarly contradictory. Regarding HDL-C,
some show a positive association between low HDL-C
levels and increased BC risk [29,39-42] and a protective ef-
fect of high HDL to premenopausal BC [43]; while others
find no association [44-46], and some even report a posi-
tive correlation between high HDL-C and BC risk [47,48].
LDL-C is less studied and no association with BC risk was
reported [29,31]. Triglycerides levels were no longer associ-
ated with risk in prospective studies except, when in com-
bination with low HDL [33,43].
Different study designs, study populations and end-
points, duration of follow up, timing of cholesterol
measurements, tumor stage and histological type, and
differences in statistical adjustment for confounding
variables may account for the disparity in the results of
these studies.
Although the inconsistency of the studies in the influ-
ence of plasma cholesterol on BC risk, alterations in
lipid profile, are often seen among BC patients, when
compared to non-cancer controls. Increased TC levels
are transversal to all studies [41,49-54] with the excep-
tion to advanced cases in two studies [55,56]. Triglycer-
ides and LDL, when measured, were also constantly
raised while HDL level was decreased [41,49-54,57].
So, whereas from the epidemiological point of view,
the influence of plasma cholesterol in BC initiation hasbeen difficult to demonstrate, the variations of lipid pro-
file in BC patients and controlled experimental studies
suggest a role of cholesterol in BC progression.
In the present study we hypothesized that the host
cholesterol-enriched macroenvironment, promotes breast
tumor progression. To answer this question we prospect-
ively assessed the lipid profile in a cohort of women with
BC, at diagnosis, and correlated these levels with clinical
and pathological data collected thereafter.
Methods
Study population and data collection
From January to December 2011, women, who underwent
for operable BC at the Breast Unit of Instituto Português
de Oncologia de Lisboa, Francisco Gentil (IPOLFG), were
prospectively assembled.
Women were included if they met the following
criteria: 1) invasive ductal carcinoma (currently named
invasive carcinoma NOS [58]), confirmed by biopsy; 2)
surgery as the first treatment; 3) informed consent.
Women were excluded if they had: 1) previous treatment
(chemotherapy, radiotherapy, hormonotherapy); 2) heredi-
tary BC (confirmed by genetic analysis) or 3) were taking
lipid-lowering, anti-diabetic drugs (statins, fibrates, oral
anti diabetics, Insulin) or corticosteroids in the previous
year. The study was approved by the Ethics Committee of
the IPOLFG.
Demography, risk factors [menopausal status, body
mass index (BMI), age, family history, parity, breast feed-
ing] and clinical examination were recorded in the first
interview.
Treatment was determined by the clinicopathological
stage and patient characteristics according to the institu-
tional protocols (following NCCN guidelines [59]), with-
out changes related to the study.
Follow up, after surgery and adjuvant treatment (when
appropriate), was scheduled every 6 months for 2 years
and annual thereafter. Mammography was performed
1 year after surgery and then repeated yearly.
Biospecimen collection and plasma lipid and
lipoproteins assays
Fasting lipid profile was measured at diagnosis, along
with routine preoperative exams. Blood was collected
into EDTA-coated tubes and the plasma levels of total
cholesterol (TC), low density lipoprotein (LDL-C), high
density lipoprotein (HDL-C) and triglycerides were mea-
sured automatically by electrophoresis (Architect ci8200
analyzer; Abbott Diagnostics, Wiesbaden, Germany) at
the certified Clinical Pathology Laboratory of IPOLFG.
Pathology and Immunohistochemistry
Hormonal receptors were measured using standardized
immunohistochemistry. Her2-neu receptor was scored
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[60] from 0 to 3+. All cases with 2+ score were reevalu-
ated using chromogenic in situ hybridation. Immunohis-
tochemical staining for Ki 67 was performed in a Dako
Autostainer® (Dako, Glostrup, Denmark) using standard
protocols, followed by counting positive cells in an auto-
mated cellular imaging system (ACISW II, Dako, Glostrup,
Denmark I). Technicians were blinded to the lipid profile
status of the study participants.
Statistical analysis
Continuous variables are presented as mean (standard
deviation) or median (interquartile range) if they have
normal distribution or not, respectively. For categorical
variables absolute values and frequencies are shown.
Spearman rank correlations coefficients were calculated
to examine correlations between continuous variables.
Univariate analysis between lipid profile, BC risk fac-
tors [status, body mass index (BMI), age, family history,
parity, breast feeding] and traditional prognostic factors
[tumor size, positive lymph nodes, tumor grade, lympho-
vascular invasion (LVI), estrogen receptor (ER), proges-
terone receptor (PR), Her2-neu receptor (HER2) and Ki
67] were performed using parametric tests to variables
with normal distribution and non-parametric tests to
variables without normal distribution.
Multivariate logistic regression to the risk of tumor T
stage included the following variables: TC (by tertiles),
LDL (by tertiles), Triglycerides (3rd tertile), BMI (by ter-
tiles) and age (by tertiles) by using stepwise conditional
forward analysis method (entry 0,05; removal 0,10).
Kaplan-Meier curves were used to determine overall
survival (OS) and disease-free survival (DFS) rates with
use of log rank tests. Cox proportional hazards models
were used to estimate hazard ratios with 95% confidence
intervals (CI), relating LDL level to DFS. Multivariate
Cox model was adjusted to tumor T stage, N stage and
subtype.
To assess the internal validity of our results we exam-
ined the association of lipid profile with BMI and age. The
association of BMI and tumor characteristics, as well as
OS and DFS adjusted to BMI were also determined.
For statistical purposes, cases were censored at the
date of disease progression confirmation, death or at
June 9th, 2013, whichever came first.
Likelihood ratio P values are reported to whole vari-
ables in the model. All P values are two-tailed.
The statistical analysis was done using IBM SPSS
Statistics for Windows, Version 19.0(Armonk, NY: IBM
Corp. Released 2010).
Results
A total of 446 women were potential assembled to the
study. Of those, 202 were excluded for being on conflictingmedications (n = 134), for BC histological type (n = 60) and
previous treatments (n = 9). Baseline demographic, clinical
and tumor related characteristics of the study population
(n = 244) are listed in Table 1.
All women underwent surgery, being the majority
treated with breast-conserving surgery (73,8%); 78,3% had
adjuvant radiotherapy; 67,7% had systemic chemotherapy;
11,9% are under trastuzumab and 70,1% are under hor-
mone therapy (Additional file 1).
During follow up, 1 woman had local disease relapse,
16 women had systemic dissemination and 9 died (7
from confirmed disease progression) (Additional file 2).
Spearman correlations
Exploratory correlations between lipid profile, age, BMI,
primary tumor size and lymph node metastasis ratio (de-
fined as the number of metastatic axillary lymph nodes,
over the total lymph nodes removed), showed that sys-
temic levels of LDL-C and TC correlates positively with
tumor size (Spearman r = 0,199, P 0,002; Spearman r =
0,145, P 0,025, respectively). As expected, age correlates
with BMI (Spearman r = 0,155, P 0,022) and triglycerides
(Spearman r = 0,312, P <0, 0001) and BMI correlates with
age, LDL-C (Spearman r = 0,161, P 0,018), HDL (Spearman
r = −0,157, P 0,021) and triglycerides (Spearman r = 0,149,
P 0,027).
Plasma LDL-C level was significantly related to tumor
T stage and prognostic groups of the American Joint
Committee on Cancer [58]. There was no statistical dif-
ference in other parameters of lipid profile across tumor
stages (Additional file 3) and we did not find correla-
tions between pathological or clinical data and lipid pro-
file variables (Additional file 4).
Univariate associations
Population was stratified based on LDL-C level tertiles:
LDL T1:LDL-C ≤ 117 mg/dl; LDL T2:144 mg/dl ≥ LDL-
C > 117 mg/dl; LDL T3:LDL-C > 144 mg/dl. Patients in
the third LDL-C tertile have larger tumors (P 0,024)
(Figure 1A), of higher differentiation grade (P 0,027), with
higher proliferative rate (P 0,017), and are diagnosed in
more advanced stages. This analysis does not demonstrate
differences in lipid profiles between breast tumor immu-
nohistochemical subtypes (Luminal A, Luminal B, Triple
negative and HER2 type [61]). Nevertheless, tumors of
patients in the third LDL-C tertile are more commonly
Her2-neu positive, when compared to others tertiles
(P 0,002) (Figure 1B). There are no differences, between
LDL-C categories, concerning studied BC risk factors
(Additional file 5).
Multivariate logistic regression
A multivariate logistic regression to the risk of tumor T
stage was then modeled. All the variables significantly
Table 1 Clinical and tumor-related characteristics of the study population (N = 244)
Characteristics No. of patients %1
Patient characteristics
Age (Years), mean±SD (range) 58,2±13,3 (29-91)
Weight (Kg), median (interquartile range) 67 (60-76)
Height (cm), median (interquartile range) 160 (154-163)
BMI (Kg/m2), median (interquartile range) 26,7 (23,5-30,44)
Menopausal status (yes) 126 65,6
Gestation (yes) 182 90,54
Breast-feeding (yes) 146 79,3
Oral contraception/HT (yes) 96 55,6
Family history of BC♯ (yes) 56 27,5
TC (mg/dL), median (interquartile range) 209,5 (191-231)
HDL-C (mg/dL), median (interquartile range) 53 (46-60)
LDL-C (mg/dL), median (interquartile range) 128 (110-153)
Triglycerides (mg/dL), median (interquartile range) 94 (74,5-126)
Tumor characteristics2
Histological type IDC 244 100
Tumor size (mm), median (interquartile range) 21 (14-30)
Tumor stage (T) T1, ≤ 2 cm 122 50
T2, 2-5 cm 115 47,2
T3, >5 cm 7 2,8
Tumor differentiation grade G1 27 12,4
G2 134 61,5
G3 57 26,2
Immunohistochemical subtypes ER/PR positive 204 83,9
Triple negative 23 9,5
HER 2 Type 16 6,6
LVI positive 61 29,2
Nodal stage (N) N0 137 56,9
N1, 1-3 LN+ 72 29,9
N2, 4-9 LN+ 18 7,47
N3, ≥10 LN+ 14 5,8
Clinical stage I 84 34,4
II 125 51,3
III 35 14,3
Bilaterality (yes) 10 4,1
¹Frequency of known cases.
2Tumor characteristics based on The American Joint Committee on Cancer [58].
Histological type of breast cancer (IDC is presently named invasive carcinoma, NOS); Tumor Stage T of TNM Classification (T1≤2cm; T2:2-5cm; T3>5 cm); Tumor
Differentiation Grade of Nothingham Histologic Score (G1, G2, G3); Immunohistochemical subtypes [Luminal A and B (ER/PR positive); Triple negative (ER/PR negative
and Her2-neu negative); HER2 Type (ER/PR negative and Her2-neu positive)]; Pathological axillar Nodal Stage of TNM Classification (N0: no metastatic LN; N1: 1-3 metas-
tatic LN; N2:4-9 metastatic lymph nodes; N3≥10 metastatic lymph nodes); Clinical Stage or Prognostic Stages Groups of American Joint Committee on Cancer (I, II, III,IV).
HT: Hormonal Therapy; BC: Breast Cancer; BMI: Body Mass Index; HT: Hormonal Therapy; TC: Total Cholesterol; LDL-C: Low Density Lipoprotein; HDL-C: High Density
Lipoprotein IDC: Invasive Ductal Carcinoma; ER: Estrogen Receptor; PR: Progesterone Receptor; LVI: Lymphovascular Invasion; LN: Lymph Nodes.
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Figure 1 Tumor characteristics in LDL-C tertiles groups. A. Tumor size increases across LDL-C tertiles groups. Line represents the median
value of tumor size in each LDL-C tertile. B. Frequency of tumor characteristics in LDL-C tertiles groups. *1LDL T1-T2 (Her2-neu positive15,5%) vs
LDL T3 (Her2-neu positive 27,8%): OR 5,015 (1,678-14,988) P 0,002. *2LDL T1 (Stage II-III 54,9%) vs LDL T2-T3 (Stage II-III 69,6%): OR 0,543
(0,313-0,943) P 0,029. Kruskall-Wallis test. ER: Estrogen Receptor; PR: Progesterone Receptor; LVI: Lymphovascular Invasion; LN: Lymph Nodes.
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introduced. Age and BMI, even not positively associated,
were also included because of its strong correlation with
lipid profile. It was found that the LDL-C level > is a
predictor factor to tumor size ≥ 20 mm, at diagnosis
(Table 2).
Survival and cox regression model
At 25 months of follow up the DFS in LDL T1, LDL T2
and LDL T3 groups was 100%, 90,6% and 88,3%, respect-
ively (log rank test 0,013) (Figure 2A). OS had no statisti-
cally significant differences between LDL-C tertiles groups
(Figure 2B).
Cox regression model to DFS, adjusted to tumor T and
N stages, and BC immunohistochemical subtypes, revealed
that LDL-C higher than 117, mg/dL, at diagnosis, is associ-
ated with poor disease-free survival (HR 0,129; CI 0,017-0,
978, P 0,048) (Table 3).
Discussion
Multiple epidemiological studies exploring causal associ-
ations between dyslipidemia and BC incidence produced
contradictory results [24-37]. Several methodological
aspects may explain the diverse conclusions, but the in-
fluence of cholesterol in BC risk remains to be clinical
demonstrated.Table 2 Univariate and multivariate logistic regression to the
Univariate analysis
Variable HR 95% CI
Total cholesterol T≥2vs T1 1,912 1,113-3,285
LDL-C (>117mg/dl) T≥2vs T1 2,419 1,394-4,199
Triglycerides T3 1,888 1,092-3,264
BMI T≥2vs T1 1,785 0,010-3,155
Age T≥2vs T1 0,833 0,430-1,416
LDL-C: Low Density Lipoprotein; BMI: body mass index; HR: hazard ratio, CI: confideNevertheless, biological clues from laboratory [13-19]
and in vivo pre-clinical studies [20-23], as well as signifi-
cant alterations in lipid profile of BC patients compared
to healthy controls [41-49,56,57,62,63], are very suggest-
ive for a role of cholesterol in BC progression.
In the present study, fasting lipid profile (with discrim-
ination between lipids and lipoproteins fractions) was
prospectively assessed in a cohort of patients with invasive
carcinoma, in initial stages, before any treatment and with
no history of being on antidiabetic or lipid lowering drugs
(including statins, fibrates, oral antidiabetics, insulin or
corticosteroids). Population characteristics are similar to
other series, concerning to demographic and tumor char-
acteristics [64-66]. A slight under-representation of triple
negative and HER2 type cancer have occurred due to
the inclusion criteria, as those patients are more likely
to undergo neoadjuvant chemotherapy. The average
lipid profile of BC patients in this cohort superimposes
that of the sex, age and BMI-matched portuguese popu-
lation [67,68].
Results show that systemic LDL-C level above 117 mg/dL
is a predictive factor of tumor T stage, at diagnosis. These
levels are also positively associated with worse prognostic
characteristics such as higher histological grade, higher
proliferative rate [69] and more advanced clinical stage
(II-III). Patients in the third tercile (LDL-C >144 mg/dl)risk of tumor size ≥20 mm
Multivariate analysis
P value HR 95% CI P value
0,018





Figure 2 Overall and disease-free survival in LDL-C tertiles groups. Kaplan–Meier Curves. A. At 25 months, overall survival is 100% in LDL T1,
92,8% in LDL T2 and 97,2% in LDL T3 (Log rank test P 0,066). B. At 25 months, disease-free survival is 100% in LDL T1, 90,6% in LDL T2 and 88,3%
in LDL T3 (Log rank test 0,013).
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sis. This trend seems to be transversal to all immunohisto-
chemical BC subtypes, although we found a significant
higher number of Her2-neu positive cases in patients of
the third tertile group.
Other published studies, also focused on assessing lipid
profile in BC patients, found higher TC levels in BC pa-
tients, compared to healthy control patients [50,52] and
also an association between increased TC, LDL-C and de-
creased HDL-C levels with increasing tumor stage [50].
To our knowledge this is the first cohort of BC pa-
tients in which the correlation of lipid profile and tumor
characteristics was done in a setting of pre-treatment
and with all patients free of lipid lowering drugs. Despite
we did not accessed variables that may also influence the
lipid profile such as smoking habits, type of diet, resi-
dence area or socioeconomic status, the most importantTable 3 Cox multivariate regression model for
disease-free survival
Variable HR 95% CI P value
Tumor T stage (≥T2) 0,822 0,264-2,565 0,736
Tumor N stage (≥N1) 0,551 0,201-1,515 0,248
LDL-C (> 117 mg/dL) 0,129 0,017-0,978 0,048
Luminal A (yes) 0,599 0,072-5,017 0,637
Luminal B (yes) 0,532 0,047-6,026 0,610
Triple negative (yes) 0,128 0,015-1,111 0,062
HER2 type (yes)a – – –
aDegree of freedom reduced because of constant or linearly
dependent covariates.
LDL-C: Low Density Lipoprotein; T and N: TNM stages; HR: hazard ratio,
CI: confidence interval.co-variables, BMI, age and lipid lowering drugs were
controlled.
Furthermore, we prospectively followed-up the patients,
and at 25 months of follow up, overall survival did not evi-
denced differences but DFS of the patients in the third
LDL-C tertile, at diagnosis was significantly reduced (88,3%
vs 100%, P 0,013). Differences of DFS in the LDL tertiles
groups, adjusted to BMI remains statistically significant
(Additional file 7). Cox regression model shows that LDL-
C level at diagnosis is inversely correlated with DFS, even
considering tumor T and N stages and immunohistochem-
ical subtypes covariates.
We found that LDL-C fraction is significantly associ-
ated with BC progression and may actually be useful in
the identification and medical follow-up of high-risk
groups. LDL-C levels at diagnosis therefore emerge as a
prognostic factor in BC patients.
For operable BC, two years of follow up may be short,
but is also reported that disease relapse has a peak of in-
cidence in the first two years after diagnosis [70,71]. As
a limitation we could not avoid the possible influence of
adjuvant treatment either in lipid profile or disease pro-
gression, once no modification to the routine protocols
was introduced. Nevertheless the strong association of
LDL-C level and tumor size before treatment favors the
LDL-C as a putative prognostic biomarker. It is also not
possible to exclude the common association of choles-
terol levels, obesity and the variance in health awareness
before diagnosis. However results were adjusted to BMI
and, during follow up, all women were evolved in the
same program of surveillance and health control.
We can speculate that high LDL-C levels in patients
with aggressive (high stage/ high grade) primary tumors
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tor, in patients with chronic hypercholesterolemia. But,
on the other hand, the high LDL-C levels that we ob-
served may actually reflect a shift in cholesterol synthe-
sis (by the liver or tumor cells themselves) in patients
with aggressive tumors; accordingly, Zielinski et al. [72]
followed-up a group of patients with advanced BC in re-
mission and described a significant rise in plasma chol-
esterol and triglycerides in most of those who developed
disease progression.
Considering that proliferating cancer cells have an in-
creased demanding of cholesterol and intermediates of
cholesterol biosynthesis pathway, the up-regulation of
cholesterol biosynthesis and reduced cellular efflux are
expected. In cancer cells, cholesterol synthesis has been
shown to be increased, due to availability of precursors
or to increased transcription [73], and this may have
contributed to BC carcinogenesis [74,75]. Hidroxi-3-
methyl-glutaril-coA reductase 3 inhibition by statins
decreases in vitro cell proliferation, attesting that chol-
esterol biosynthesis should be important to tumor growth
[74]. Moreover, elevated cholesterol content is charac-
teristic of breast tumors [76] and acyl-CoA: cholesterol
acyltransferase 1 inhibition, an enzyme involved in choles-
teryl esterification decreases proliferation and invasion
rate [13].
However, despite cancer cells increases intracellular chol-
esterol synthesis, this effect is not expected to produce
hypercholesterolemia and justify the observed associations.
Some other published data supports the notion that
cancer cells are able to uptake cholesterol from the
bloodstream. High LDL-C receptor expression was dem-
onstrated in BC tissue, compared to normal tissue [77].
So plasma LDL-C could be used by cancer cells. In
in vitro experiments, was also demonstrated that cancer
cells can also consume HDL-C through the scavenger
receptor class B, type I (SR-BI) [15,16,78] and exogenous
triglycerides [79]. In our clinical setting HDL-C or tri-
glycerides measurements did not show suspicious modi-
fications, but our results do not rule out the possibility
of cancer cells consume.
Corroborating this hypothesis are laboratory studies
showing that both exogenous LDL-C and HDL-C can pro-
mote proliferation and migration, features of aggressive tu-
mors [14-16]. Also animal studies showed a higher tumor
and metastatic burden [21] as well as disease progression
[22,23] in hypercholesterolemic mice compared with non-
hypercholesterolemic controls.
The exogenous cholesterol could be mobilized from
body storage, through HDL-C or from diet, through hep-
atic metabolism and LDL-C. Mobilization is not likely to
contribute to hyperlipidemia, since we saw the same
pattern of lipid profile in BC patients and in the age and
sex-matched non-cancer portuguese population [67,68].High LDL-C and low HDL-C is the most common
lipid profile induced by western diet and is highly fre-
quent [80].
Initial studies on cholesterol and cancer showed an in-
creased risk in patients with lower plasma cholesterol.
Once demonstrated that reduction in cholesterol level
does not cause cancer this has been assumed as a pre-
clinical effect of malignancy considering that cancer cells
up take cholesterol and decreases its levels. [62,63]. We
found an association of LDL-C with large tumors, but all
tumors were at very initial clinical phase, many of them
diagnosed in screening programs.
The causal relationship between systemic cholesterol
has been hard to demonstrate because of the length of
time to the event, multifactorial etiology of BC, con-
comitant medication, statistical analysis and event defini-
tions. However, assuming that cholesterol is essential to
cell proliferation, once a tumor develops in a hypercholes-
terolemic environment it is well adapted to progress and
this may be the explanation for the observed association
of LDL-C level, tumor size and disease progression.
We also found that tumors of the LDL-C highest tertile
are more commonly Her2-neu (ErbB2) positive. Moreover,
as mentioned earlier, membrane cholesterol is specially lo-
calized in the lipid rafts domains. Such areas are enriched
in transmembrane molecules that are key in signaling path-
ways associated with malignant progression: Fas receptor,
TNF related apoptosis-inducing ligand, AKT, integrins, cad-
herins and growth factor receptors [8] including ErbB2.
The later is a tyrosine kinase receptor (and oncogene) local-
ized in lipid rafts and its function is highly dependent on
membrane fluidity [81,82]; cholesterol enrichment within
the cell may therefore alter receptor-signaling. It is possible
that ErbB2 receptor ligand-independent activation is poten-
tiated by cholesterol-enriched environment, explaining a se-
lection of Her2-neu positive tumors.
Although synthesis of estrogen and progesterone
require cholesterol, no association of LDL-C and ER sta-
tus was seen. In vitro and in vivo studies have showed
contradictory results concerning the effect of choles-
terol, in promoting ER positive breast cancer prolifera-
tion [14,20].
The pro-inflammatory microenvironment induced by
high-cholesterol levels, as seen in atherosclerosis, in
which LDL-C is the most important causative factor
[83,84], can also play an effect on BC initiation and pro-
gression. The use of statins before cancer diagnosis re-
duces cancer related mortality [85]; the reduction of
LDL-C is supposed to be the main mechanism through
which statins exert effect, but the anti-inflammatory ef-
fect cannot be ruled out.
In our prospective study, patients with high levels of
LDL-C at diagnosis had reduced disease free survival,
even adjusting to tumor type, stage and BMI. This may
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tasis development or that hypercholesterolemia previ-
ously selected aggressive tumors but reinforces a role for
systemic cholesterol in BC progression and cholesterol
metabolism as a therapeutic target.
Conclusion
We found that LDL-C fraction is significantly associated
with BC progression and may actually be useful in the
identification and follow-up of high-risk groups of BC
patients. LDL-C levels at diagnosis, therefore emerge as
a prognostic factor in BC. Additionally, results support a
role for systemic cholesterol in BC progression and indi-
cate that cholesterol metabolism could be a therapeutic
target in BC treatment.
Additional files
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